Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 5/20 | 0.48 |
| ▸ | EGFR | P00533 | 3/20 | 0.48 |
| ▸ | ABL1 | P00519 | 2/20 | 0.45 |
| ▸ | ABL2 | P42684 | 2/20 | 0.45 |
| ▸ | PARP1 | P09874 | 4/20 | 0.43 |
| ▸ | PARP2 | Q9UGN5 | 4/20 | 0.43 |
| ▸ | PRKCG | P05129 | 1/20 | 0.43 |
| ▸ | PRKCB | P05771 | 1/20 | 0.43 |
| ▸ | PRKCA | P17252 | 1/20 | 0.43 |
| ▸ | PRKCH | P24723 | 1/20 | 0.43 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.43 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.38 |
| ▸ | IL1B | P01584 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12062412 | 0.86 | OPRM1 (0.40) | PRKCGPRKCBPRKCAPRKCHPRKCE | |
| SCHEMBL14193 | 0.77 | SRC (0.44) | SRCEGFRABL1ABL2PARP1 | |
| SCHEMBL30087102 | 0.72 | HCAR1 (0.51) | SRCEGFRABL1ABL2PRKCG | |
| SCHEMBL13968 | 0.72 | HCAR1 (0.51) | SRCEGFRABL1ABL2PRKCG | |
| SCHEMBL8304914 | 0.71 | SRC (0.43) | SRCEGFRABL1ABL2USP30 | |
| SCHEMBL8639265 | 0.71 | SRC (0.43) | SRCEGFRABL1ABL2USP30 | |
| SCHEMBL3963276 | 0.71 | PRKCG (0.49) | SRCEGFRPRKCGPRKCBPRKCA | |
| SCHEMBL24424726 | 0.71 | L3MBTL1 (0.60) | SRCEGFRPRKCGPRKCBPRKCA | |
| SCHEMBL4418493 | 0.71 | L3MBTL1 (0.60) | SRCEGFRPRKCGPRKCBPRKCA | |
| SCHEMBL4411954 | 0.71 | L3MBTL1 (0.60) | SRCEGFRPRKCGPRKCBPRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160031893-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | BioVersys AG (CH) | 2016-02-04 | — | — | US | disclosed |
| US-9193731-B2 | Antimicrobial compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| WO-2011047319-A2 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | RIB-X PHARMACEUTICALS, INC. (US) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031893-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | MPO, LPO, CAT | SRC 4488/4885EGFR 4722/4885ABL1 2715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.